APPENDIX

Schedule of events										
Procedures	Screening Part 1	Screening Part 2	**Day 0[3]**	Day 1	Day 2–6	Day 7±1	Day 8–13	Day 14±2	Day 15–27	Day 28±3
Informed consent	X									
Demographics	X									
Medical history	X									
Concomitant medication	X		**X**	X		X		X		X
Physical examination and vital signs	X		**X**	X		X				X
Pain NRS (in clinic)	X	X	**X**	X		X				X
Lidocaine test injection		X								
CESI			**X**			X		(X)[4]		X
IIEF-5			**X**			X		(X)[4]		X
Injection of lidocaine study formulation			**X**							
Blood sample[1]		X	**X**	X		X				
Ultrasound			**X**			X				X
Telephone followup								X		
NRS diary (at home)[2]	X		**X**	X	X	X	X	X	X	
Adverse events evaluation			**X**	X		X		X		X

[1]Blood is drawn at the second screening for baseline electrolyte panel, kidney function and blood cell count and on day 0 (one-hour post injection,) on day 1 and on day 7±1 to determine lidocaine serum levels. [2]Subjects record their NRS three times a day for the first 14 days and then once daily for the remaining study period. [3]Day 0 is the study treatment day (7–21 days after injection of lidocaine test injection). [4]On day 14±2 subjects are asked the questions from CESI and IIEF-5 over the phone. CESI: chronic epididymitis symptom index; IIEF-5: International Index of Erectile Function; NRS: numerical rating scale.